Chronic Lymphocytic Leukemia

Disease State Hub

Featured

Research Summary
Research Summary
12/16/2025
Anthony Calabro, MA
Investigators evaluating the novel Bruton's Tyrosine Kinase degrader bexobrutideg (NX-5948) reported updated Phase 1a results demonstrating rapid and durable clinical responses in heavily pretreated...
12/16/2025
CONFERENCE COVERAGE
CONFERENCE COVERAGE
12/12/2025
Anthony Calabro, MA
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
12/12/2025
Pop Quiz
Pop Quiz
12/09/2025
Anthony Calabro, MA
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
12/09/2025

Interactive Features

Pop Quiz
Pop Quiz
12/09/2025
Anthony Calabro, MA
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
12/09/2025
Pop Quiz
Pop Quiz
11/11/2025
Miranda Manier, BA
Core needle biopsy accuracy varies by lymphoma subtype. Which one yields the highest diagnostic sensitivity? Test your knowledge of hematologic pathology.
11/11/2025
Pop Quiz
Pop Quiz
10/14/2025
Miranda Manier, BA
Richter transformation of chronic lymphocytic leukemia carries poor outcomes with traditional therapies, but emerging treatments may improve survival. Test your knowledge of prognosis by taking this quick...
10/14/2025
Pop Quiz
Pop Quiz
09/17/2025
Anthony Calabro, MA
How well do you understand the latest findings on fixed-duration acalabrutinib–venetoclax regimens in untreated chronic lymphocytic leukemia? Take this quiz to find out!
09/17/2025
Pop Quiz
Pop Quiz
08/13/2025
Anthony Calabro, MA
The survival outcomes for patients diagnosed with this chronic lymphocytic leukemia complication have remained poor for decades. Can you name the complication? Take the quiz to find out!
08/13/2025

Clinical Insights

Expert Q&A
Expert Q&A
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025